ExpreS2ion’s Board and Management committed to fully exercise their TO5 warrants
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, August 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company’s Board and Management intend to fully exercise their TO5 holdings during the subscription period in September 2021. This